Phelan-McDermid syndrome — the neurodevelopmental disorder caused by deletion or mutation of the SHANK3 gene on chromosome 22q13.3, characterized by severe intellectual disability, autism spectrum disorder, hypotonia, speech absence, and seizures — has historically been managed entirely through supportive and behavioral interventions, but the Phelan McDermid Syndrome Market is now reflecting unprecedented pharmaceutical interest as the SHANK3 synaptic scaffolding protein becomes a tractable target for neurodevelopmental drug development.

Insulin-like growth factor-1 (IGF-1) and trofinetide — the investigation of IGF-1 (mecasermin, Increlex) and the synthetic analogue trofinetide (Daybue, Acadia Pharmaceuticals) in Phelan-McDermid and related synaptopathies, based on preclinical evidence that IGF-1 signaling enhances synaptic maturation and compensates for SHANK3 haploinsufficiency. The Phase 2 trials of intranasal IGF-1 demonstrating improvements in social responsiveness and repetitive behaviors in small Phelan-McDermid cohorts, while trofinetide's approval for Rett syndrome in 2023 has created the regulatory and commercial precedent for neurodevelopmental disorder pharmacotherapy that may accelerate Phelan-McDermid-specific development.

SHANK3 gene replacement and antisense strategies — the preclinical development of AAV9-mediated SHANK3 gene therapy for mouse models showing restoration of synaptic function and behavioral phenotypes, with the challenge of blood-brain barrier delivery and the large SHANK3 cDNA requiring creative vector engineering. The antisense oligonucleotide approaches for specific splice-site mutations and the investigation of histone deacetylase inhibitors to increase SHANK3 expression from the remaining wild-type allele, representing the diverse therapeutic modalities converging on this single-gene disorder.

Multidisciplinary supportive care infrastructure — the standard of care encompassing early intensive behavioral intervention (ABA), speech-generating devices and AAC systems for nonverbal patients, physical therapy for hypotonia and ataxia, antiepileptic management (valproate, levetiracetam, lamotrigine for the fifty to seventy percent with seizures), and gastrointestinal management of reflux and constipation. The transition from pediatric to adult care requiring specialized neurodevelopmental disability medicine, psychiatric management of emerging behavioral phenotypes, and residential support planning.

Do you think the success of trofinetide in Rett syndrome will fast-track IGF-1 pathway drugs for Phelan-McDermid syndrome, or will the phenotypic heterogeneity and lack of validated clinical endpoints specific to SHANK3 disorders delay regulatory approval?

What is Phelan-McDermid syndrome, and what causes it? Genetics: Deletion or mutation of SHANK3 gene at chromosome 22q13.3; most cases (75%) are de novo terminal deletions of 22q13; intragenic SHANK3 point mutations or small deletions account for ~25%; inheritance autosomal dominant but rarely familial due to low reproductive fitness. SHANK3 function: Postsynaptic density protein at excitatory glutamatergic synapses; links NMDA and metabotropic glutamate receptors to actin cytoskeleton; essential for synapse formation, maturation, and maintenance; haploinsufficiency disrupts synaptic plasticity. Clinical features: Developmental delay apparent in infancy; severe to profound intellectual disability (100%); autism spectrum disorder (84-94%); absent or severely delayed speech (72% nonverbal); hypotonia (80%); motor delays; gait abnormalities; seizures (50-70%); renal abnormalities (structural defects); gastrointestinal issues (GERD, constipation, cyclic vomiting); dysmorphic features (long eyelashes, full cheeks, hypotonic facies, large hands, fleshy palms); sleep disturbances; behavioral issues (self-injury, aggression, mood lability). Prevalence: Estimated 1:15,000-1:50,000; likely underdiagnosed; both sexes affected equally.

What is the current standard of care for Phelan-McDermid syndrome? Developmental therapies: Early intervention (physical, occupational, speech therapy starting in infancy); applied behavior analysis (ABA) for autism-related behaviors; augmentative and alternative communication (AAC) devices — speech-generating devices, picture exchange systems, sign language; educational planning through IDEA/special education services; sensory integration therapy. Medical management: Seizures — antiepileptic drugs (valproic acid, levetiracetam, lamotrigine, clobazam; often polytherapy required; vagus nerve stimulation or ketogenic diet in refractory cases); Gastrointestinal — proton pump inhibitors or H2 blockers for GERD; bowel regimen for constipation; feeding therapy; G-tube placement if aspiration risk or failure to thrive. Neurological: Physical therapy for hypotonia and ataxia; ankle-foot orthoses; wheelchair or gait trainer if needed; monitoring for scoliosis and hip dysplasia. Psychiatric/behavioral: SSRIs for anxiety/OCD features; atypical antipsychotics for severe self-injury or aggression (risperidone, aripiprazole); melatonin or clonidine for sleep disturbance; structured behavioral interventions. Surveillance: Annual renal ultrasound (structural abnormalities); EEG if seizure suspicion; sleep study if OSA symptoms; regular hearing and vision screening; cardiac evaluation if indicated. Adult transition: Specialized neurodevelopmental disability medicine; residential and vocational support; guardianship planning; ongoing seizure and behavioral management.

What emerging therapies are being investigated for Phelan-McDermid syndrome? IGF-1 pathway: Intranasal IGF-1 (early Phase 2) — rationale that IGF-1 promotes synaptic maturation and compensates for SHANK3 deficiency; small studies showed improvements in social withdrawal and repetitive behaviors; mechanism distinct from growth hormone action. Trofinetide (Daybue): Approved for Rett syndrome (2023); synthetic analogue of glypromate (IGF-1 cleavage product); modulates neuroinflammation and synaptic function; theoretical applicability to other MECP2/SHANK3-related synaptopathies; no Phelan-McDermid-specific trials announced but mechanism of interest. Gene therapy: AAV9-SHANK3 preclinical studies in mouse models showed rescue of synaptic and behavioral phenotypes; challenges include SHANK3 cDNA size (too large for standard AAV), need for neuronal-specific expression, and blood-brain barrier delivery; dual-vector or mini-gene approaches under investigation. Antisense oligonucleotides: For patients with specific splice-site mutations causing exon skipping or aberrant splicing; theoretical applicability to subset of patients; no clinical trials yet. HDAC inhibitors: Preclinical data suggest increasing SHANK3 expression from wild-type allele; valproic acid has HDAC inhibitory activity but not specific enough; investigational HDAC inhibitors being explored. Metabotropic glutamate receptor modulators: SHANK3 haploinsufficiency affects mGluR5 signaling; positive and negative allosteric modulators being investigated in related autism models.

#PhelanMcDermid #SHANK3 #AutismSpectrumDisorder #RareDisease #NeurodevelopmentalDisorder #Synaptopathy